Floatz logo

Entinostat

ER-Negative PR-Negative HER2-Negative Breast Cancer

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

448 Active assets in the ER-Negative PR-Negative HER2-Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Atezolizumab
European Institute of Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Entinostat is also rated in:

Stage IIIA Non-Small Cell Lung CancerDormant
BB
Indicative ·
69 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
62 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →